VCELVericel Corporation

$2B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$27M+22.3% YoY

Gross Profit

$17M62.8% margin

Operating Income

-$5M-19.0% margin

Net Income

-$5M-17.6% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

-32.3%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$4M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$150M

Total Liabilities

$40M

Stockholders' Equity

$110M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$22M	+22.3%
Gross Profit	$17M	$13M	+27.2%
Operating Income	-$5M	-$3M	-51.2%
Net Income	-$5M	-$3M	-65.4%

VCEL Q1 2020 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena